Clinical Research Service Articles & Analysis
20 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently unveiled its significantly enhanced online ordering system. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is thrilled to announce the launch of its new line of liposomes specifically designed for food applications, offering promising delivery systems to enhance the bioavailability, stability, and taste of various food ingredients. ...
The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio’s POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is proud to announce its expanded capabilities in Customized Liposomes. This advancement allows researchers and developers to leverage the power of liposome technology for a wider range of applications. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently expanded its low PDI polymer portfolio and announces its new offering of Polyolefin Family polymers with a wide range of properties that make them well-suited for a variety of drug delivery applications. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has launched a new line of Locust Bean Gum with advanced technical platforms to help scientists advance biopharmaceutical research. Over the past few decades, researchers have been working on developing delivery systems that can reduce side ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced a series of Magnetofection Reagents for gene expression. ...
On top of her strong enthusiasm for applications of AI and NLP technology in clinical decision support, Laurie brings a wealth of first-hand clinical research and patient pre-screening experience. Most recently, Laurie was a Vice President for Clinical Research Services at Roswell Park ...
Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. By combining xCures’ records collection, virtual screening, eConsent and data structuring technology with Vault Health’s state-of-the-art suite of ...
ByxCures
Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. ...
This allows Tongji Hospital the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. This staged installation significantly reduces the financial burden at the start of the clinical proton therapy program and minimizes the risk of technology obsolescence. ...
With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects. ...
Associate General Counsel at IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Prior to his time with IQVIA, Mr. ...
“Although the number of oncology treatments has increased, there is more work to be done to ensure all patients are getting the best, most targeted therapies for their specific diseases. Clinical research must keep pace with the rate of scientific advancement, and that means clinical trials must be accessible to more patients,” said ...
The combination is unprecedented in bringing electronic medical records, genomic data, and medical image data into one integrated network and set of AI-enabled workflows that enable leading software-as-a-service (SaaS) clinical research and clinical decision support applications. ...
The company is using this start-of-the-art federally regulated CLIA lab for its clinical diagnostic testing services. All research and development activities remain at C2N’s existing facility, which is a short distance away from the new facility. ...
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly ...